NCT00767468

Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis

A Phase IB Study of Sorafenib for Patient With Locally Advanced or Metastatic Hepatocellular Carcinoma and Child's B Cirrhosis

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: UNC Lineberger Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib in treating patients with locally advanced or metastatic liver cancer and cirrhosis.

Detailed description

OBJECTIVES: Primary * To evaluate the pharmacokinetic parameters of sorafenib tosylate in patients with locally advanced or metastatic hepatocellular carcinoma and Child-Pugh B cirrhosis. * To correlate the pharmacokinetic parameters of sorfenib tosylate with hepatic retention and clearance of technetium Tc 99m mebrofenin (MEB) and technetium Tc 99m sestamibi (MIBI). Secondary * To establish a tolerable dose of sorafenib tosylate based on degree of liver dysfunction (bilirubin ≤ 3 times upper limit of normal \[ULN\] or bilirubin \> 3 times but ≤ 6 times ULN). * To correlate the pharmacokinetics MEB and MIBI with the dose-limiting toxicity of sorafenib tosylate. * To explore whether increase in bilirubin consists primarily of conjugated or unconjugated bilirubin in response to sorafenib tosylate. * To explore whether there is a correlation between increased bilirubin and decreased clearance of MEB and/or MIBI. * To explore whether there is a correlation between survival and MRI characteristics associated with high tumor VEGF levels. * To assess VEGF levels directly in available biopsy samples using IHC. * To determine expression levels of hepatic transport proteins (i.e., OATPs, Pgp, or MRPs) that may correlate with clearance of sorafenib tosylate. * To explore whether there is a correlation between survival and activation of the RAF/MEK/ERK pathway at baseline. * To estimate median overall survival. OUTLINE: This is a multicenter study. Patients are stratified according to degree of hepatic dysfunction (moderate \[bilirubin ≤ 3 times upper limit of normal (ULN)\] vs severe \[bilirubin \> 3 times but ≤ 6 times ULN\]). Patients receive oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo hepatic scintigraphy with technetium Tc 99m mebrofinin (MEB) and technetium Tc 99m sestamibi (MIBI) at baseline. Blood and urine samples are collected periodically for pharmacokinetic studies. After completion of study therapy, patients are followed at 3-4 weeks and then every 3 months thereafter.

Conditions

• Liver Cancer

Interventions

Type	Name	Description
DRUG	sorafenib tosylate	Sorafenib 400mg BID until disease progression or patient withdrawal.

Timeline

• Start date: 2008-10-01
• Primary completion: 2010-02-01
• Completion: 2010-11-01
• First posted: 2008-10-07
• Last updated: 2012-05-23

Locations

2 sites across 1 country: United States